JAK2‐related pathway induces acquired erlotinib resistance in lung cancer cells harboring an epidermal growth factor receptor‐activating mutation

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, such as gefitinib and erlotinib, are effective for non‐small cell lung cancer with activating EGFR mutations. However, even in patients with an initial dramatic response to such a drug, acquired resistance develops after 6–12 months...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer Sci
Hauptverfasser: Harada, Daijiro, Takigawa, Nagio, Ochi, Nobuaki, Ninomiya, Takashi, Yasugi, Masayuki, Kubo, Toshio, Takeda, Hiromasa, Ichihara, Eiki, Ohashi, Kadoaki, Takata, Saburo, Tanimoto, Mitsune, Kiura, Katsuyuki
Format: Artigo
Sprache:Inglês
Veröffentlicht: John Wiley and Sons Inc. 2012
Schlagworte:
Original Articles
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7659254/
https://ncbi.nlm.nih.gov/pubmed/22712764
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1349-7006.2012.02363.x
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge